• Home
  • » 
  • Reports
  • » 
  • Oral Solid Dosage Manufacturing Market -...

Oral Solid Dosage Manufacturing Market

Oral Solid Dosage Manufacturing Market - Distribution by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    September 2023

  • Pages
    296

  • View Count
    9853

  • Buy Now

Example Insights

The image provides context of oral solid dose manufacturing market. The processing of complex oral solids, from formulation design to scale-up and manufacturing, is fraught with several challenges; as a result, drug developers are increasingly relying on service providers that offer integrated capabilities in this domain This image provides list of oral solid dosage manufacturing companies. Presently, over 300 companies claim to have the required expertise to offer contract manufacturing services for a broad spectrum of oral solid dosage forms, including modified release formulations of tablets and capsules The infographic looks at the oral solid dosage manufacturing companies' service portfolio distribution. Nearly 30% of the players have established end-to-end capabilities, from early development to packaging of oral solids in a variety of containers; this simplifies supplier management activities for sponsor companies The image provides details on the current oral solid dosage manufacturing market landscape. The current OSD manufacturing market landscape features the presence of both established and emerging players engaged in the manufacturing of oral solid dosages at various scales of operation, in compliance with the regulatory standards The image provides geographicl distribution of oral solid dosage manufacturing companies. With more than 1,350 facilities, oral solid contract manufacturers have established global presence; majority of these players are based in the Asia-Pacific region, primarily in countries, such as China and India
The image looks at the competitive landscape acrossc contract manufacturing organizations. Owing to the rise in demand for complex oral solid formulations, the needs of drug innovators are evolving; as a result, service providers are upgrading their technical capabilities to cater to customized requests of their clients The infographic looks at the key winning strategies for success in oral solid dosage contract manufacturing market. An analysis of the business operations of key contract manufacturers highlights growing emphasis on adopting long-term value creation strategies to respond effectively to the rising competition in this mature market The image provides details on various expansions undertaken by oral solid dosage manufacturing companies. As part of their growth strategy, CMOs are investing in either expanding their existing facilities / capabilities or building facilities in other regions; majority of these initiatives were undertaken in North America This image looks at the manufacturing capacity across OSD manufacturing companies. As part of their growth strategy, CMOs are investing in either expanding their existing facilities / capabilities or building facilities in other regions; majority of these initiatives were undertaken in North America. It includes details on capsule manufacturing companies, tablet manufacturers, tablet manufacturing companies and softgel capsules. The global installed oral solid dosage contract manufacturing capacity is spread across various geographies; over 30% of this capacity is dedicated to the manufacturing of tablets on a commercial scale The infographic looks at the demand of various oral solid dosage formaulations such as capsule manufacturing companies, tablet manufacturers, tablet manufacturing companies and softgel capsules
The image looks at the likely cost of ownership a company should expect while developing manufacturing facilities. Our proprietary total cost of ownership model offers an informed estimate of capital and operational expenses associated with the establishment and maintenance of a contract manufacturing facility, over a span of 20 years The image provides details on the estimated gap between demand vs supply of oral solid dosage formulations. The demand for oral solid dosage contract manufacturing is rising significantly owing to the growing complexity of APIs; by 2035, it is anticipated to reach over 35,000 metric tonnes, across clinical and commercial scales This image provides details on oral solid dosage manufacturing market size. Driven by volume shifts from originators to generics and over-investments to create safety buffers, the contract manufacturing domain is currently witnessing an excess in capacity, thereby propelling consolidation efforts The image provides segmentaion of oral solid dosage manufacturing market. The oral solid dosage contract manufacturing market is likely to grow at a CAGR of ~6%, till 2035; the projected opportunity is likely to be distributed across different dosage forms, scales of operation and company sizes  

Report Description

Oral Solid Dosage Manufacturing Overview

Oral solid dosage contract manufacturing market is estimated to be USD 21 billion in 2023 and is anticipated to grow at a CAGR of ~5% during the forecast period. Over the years, rising complexity of active pharmaceutical ingredients (APIs) has led to the development of a myriad of novel formulations that enable efficient drug delivery to the intended site of action. Nonetheless, the demand for oral solid dosage (OSD) forms, including tablets and capsules, remains unparalleled. In fact, over two-thirds of the total drugs prescribed worldwide are dispensed in the form of oral solids. In addition to being cost effective and relatively more stable as compared to their large molecule counterparts, these orally administered small molecules are patient-centric, and therefore play a critical role in fixing the medication adherence problem. Since the demand for oral solid drugs is rising, the development of modified oral solid formulations (including disintegrating tablets (ODTs), combination products and prolonged-, controlled-, and sustained- release dosage forms) that can improve API solubility and enhance bioavailability can offer the drug developers a huge opportunity to stand out in this mature and competitive market. However, the manufacturing of specialized solid doses, especially those containing highly potent APIs, from early development formulations to scale-up is a complex process that requires multidisciplinary expertise. Consequently, drug developers are increasingly relying on contract manufacturing companies with specialized equipment and a trained workforce to navigate the technical and routine operations-related challenges, including those associated with complex formulations, stringent regulatory requirements and multiple suppliers. Considering the immense popularity of oral solid dosage forms, especially amongst the pediatric and geriatric populations, we believe that the demand for conventional as well as modified oral solid formulations is likely to drive commendable market growth within the oral solid dosage contract manufacturing market during the forecast period.

Key Market Insights

The Oral Solid Dosage Contract Manufacturing Market: Distribution by Type of Finished Dosage Form (Tablets, Capsules, Powders, Multi-particulates and Others), Type of Packaging (Bottles, Blisters, Sachets, Inhalers and Others), Scale of Operation (Pre-commercial and Commercial), Company Size (Small, Mid-sized, Large and Very Large), Therapeutic Area (Oncological Disorders, Infectious Diseases, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Genetic Disorders, Respiratory Disorders, Immunological Disorders, and Other Disorders), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts report features an extensive study of the current market landscape, market size and future opportunity for the companies involved in providing contract services for oral solid dosage manufacturing, over the forecast period. The market report answers many key questions related to this industry.

Key Benefits Offered by Oral Solid Dosage Formulations

Oral solid dosage formulations, including tablets, capsules, granules, sachets, powders, dry powder inhalers, and lozenges represent the most preferred dosage forms that are widely accepted by patients, worldwide. These time-tested means of treatment are relatively easy to manufacture, package and transport, offer good physical and chemical stability, and facilitate simple and accurate dosing. In addition, various coating methods make them easier to swallow, and allow modification of shape and color for aesthetic purposes. Moreover, the low production costs of oral solid formulations make them an economical option for manufacturers, healthcare institutions and patients.

Need for Contract Manufacturing in the Oral Solid Dosage Market

Despite being the oldest and most-well understood formulation, oral solid dosage development and manufacturing is associated with several complications and challenges, including toxicity associated with potent APIs, complexity of formulations, deviations in quality, utility or transportation disruption and bottlenecks in process scale-up. Further, manufacturing of high-value dosage forms, including pediatric, geriatric, anti-abuse, controlled-release, and taste-masked drugs require cutting-edge technologies which are expensive to acquire. As a result, around 60-70% of the companies engaged in this industry prefer to outsource their clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs), enabling the former to focus on their core research and development competencies.

Current Opportunities for Contract Manufacturing Organizations of Oral Solid Dosage Forms

Although biologics have provided breakthroughs for the treatment of diseases with unmet medical needs, the approval of orally administered small molecule entities has been on the rise, recently. In fact, around 84% of the best-selling pharmaceuticals are administered orally. In addition, oral solid dose forms account for nearly 30% of the small molecules in the development pipeline. However, the oral solid dosage contract manufacturing market is highly competitive, as several in-house pharmaceutical operations are being converted to offer CMO services and existing service providers are expanding their service offerings. Moreover, owing to the increase in consolidation within the pharmaceutical industry, the customer base for contract manufacturers is declining. In order to navigate the growing competition, oral solid dosage contract manufacturers are making an active effort to enhance their offerings by manufacturing high and uniform quality products in a cost-effective manner, while accommodating the diverse expectations of sponsor companies. The oral solid dosage market is expected to continue to grow at a healthy rate, and as a result, we anticipate a surge in demand for the affiliated development and manufacturing support.

Current Market Landscape of Oral Solid Dosage Manufacturing Companies: Majority Companies Provide Tablet Manufacturing and Capsule Manufacturing

Presently, close to 570 contract manufacturing organizations have the required capabilities to offer services for oral solid dosage manufacturing across different scales of operation. More than 15% of these companies serve as one-stop-shops, possessing an extensive range of capabilities (from formulation and analytical development to quality, regulatory support and commercialization) to meet client requirements. 
Tablet manufacturing and capsule manufacturing are the most popular OSD manufacturing capabilities, followed by the manufacturing of powders. There are at least 350 tablet manufacturing companies and 335 capsule manufacturing companies supporting the pharmaceutical industry to meet the growing demand for oral solid dose forms. Within capsule manufacturing, the companies have capability for production of hard gelatin as well as softgel capsules, the latter being available with limited number of contract manufacturing organizations. Softgel capsules are gaining popularity owing to their nature that makes them easy to swallow and avoids any unpleasant aftertaste.

Recent Trends: Collaborations, Facility Expansions and Innovation with Continuous Manufacturing for Oral Solid Dose Products

In order to cater to the increasing demand for OSD products, several CMOs and CDMOs have established strategic partnerships with other industry players and carried out expansion projects, thereby differentiating their offerings through niche enabling technologies, formulation expertise and manufacturing capacities, across different scales of operations. In January 2022, Procaps Group acquired a 86,000 sq.ft. USFDA approved facility in Florida, US from Strides Pharma. The company aims to expand the production capacity of softgel capsules by 1.8 billion capsules each year. Another CDMO, Piramal Pharma Solutions, upgraded its oral solid dose manufacturing facility in Madhya Pradesh, India increasing its production capacity from 3 billion doses to 4.5 billion doses. As part of the upgrade, the company expanded its capability for wet granulation, direct compression, coating and packaging. As the global market demand for oral solid dosage contract manufacturing increases, more such expansions will be witnessed.

Another trend is the investment by CMOs in continuous manufacturing equipment for oral solid dosage manufacturing, particularly tablet manufacturing. In January 2023, a drug product continuous manufacturing line for oral solids became operational at WuXi STA’s WuXi city facility. The continuous manufacturing line includes equipment for dispensing, blending, lubrication, tablet compression, and coating.

Technology Trends Shaping the Oral Solid Dosage Contract Manufacturing Market

Considering the evolving customer demands and continuous updates in the regulatory requirements, innovator companies and manufacturers of oral solid dosage products must upgrade their capabilities in order to maintain dominance in the overall pharmaceutical sector. From a regulatory perspective, concepts from Industry 4.0, including quality by design (QbD) and process analytical technology (PAT) principles, are increasingly being implemented to optimize and accelerate pharmaceutical processes. In addition, the paradigm shift from batch to continuous manufacturing is instrumental in lowering the investment and operating costs, while concurrently improving the product quality and reducing the time to market. The efforts to develop more agile, responsive, and reproducible manufacturing processes are being combined with the applications of advanced technologies, including track-and trace systems, nano-milling, 3D printing technology, which enable the production of highly engineered drug products in a streamlined manner.

Oral Solid Dosage Contract Manufacturing Market Size: North America Market Growth Falls behind Asia Pacific 

The oral solid dosage form continues to play a major role in the contract manufacturing industry, representing about 60% of the market. In the foreseen future, as several promising leads move into the clinic and / or get commercialized, the oral solid dosage contract manufacturing market is projected to grow at a noteworthy rate, during the forecast period between 2023-2035. The opportunities for growth within this industry primarily exist in the high potency products as well as the niche products, including fixed dose combinations, orally disintegrating tablets, minitablets, flavored chewables, double-layered and multiple-layers tablets. In terms of geography, the oral solid dosage contract manufacturing market in the Asia-Pacific region is anticipated to grow at a relatively faster pace during the forecast period.

Key Contract Manufacturing Organizations in the Oral Solid Dosage Manufacturing Market

Examples of key CMOs engaged in this industry (which have also been captured in this report) include Aenova, Alcami, Almac, Cambrex, Catalent, Hetero Drugs, Ind-Swift, Laboratories, Lonza, and Rubicon Research. This market report includes an easily searchable excel database of all the contract manufacturers for oral solid dosage forms worldwide.

Recent Developments in Oral Solid Dosage Manufacturing Market

Several recent developments have taken place in the field of oral solid dosage manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, Bora Pharmaceuticals signed an agreement with Celltrion Partners to manufacture and commercialize a range of oral dosage form drugs across the Asia-Pacific region. 
  • In July 2023, Aenova entered into a strategic partnership with Galvita to enhance the development, formulation and production of oral dosage forms. 
  • In May 2023, Cambrex completed the expansion of 51,000 square-foot snapdragon chemistry facility in Massachusetts. 

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments as defined in the below table:

Report Attribute Details

Base Year

2022

Forecast Period

2023-2035

Market Size 2023

$21 billion

CAGR 2023-2035

~5%

Company Size

Small, Mid-Sized, Large, Very Large

Type of Finished Dosage Form

Tablet Manufacturing, Capsule Manufacturing, Multi-particulate Manufacturing, Powder Manufacturing, Others

Scale of Operation

 Pre-commercial, Commercial

Type of Packaging

Blisters, Sachets, Inhalers, Bottles, Others

Therapeutic Area

Oncological Disorder, Neurological Disorder, Cardiovascular Disorder, Infectious Disease, Metabolic Disorder, Respiratory Disorder, Immunological Disorder, Genetic Disorder, Gastrointestinal Disorder, Others
Key Geographical Regions North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa (MENA)

Key Companies Profiled

Aenova, Alcami, Almac, Cambrex, Catalent, Hetero Drugs, Ind-Swift, Laboratories, Lonza, Rubicon Research

Customization Scope

15% Free Customization Option (equivalent to 5 analysts working days)

PowerPoint Presentation (Complimentary)

Available
Excel Data Packs (Complimentary) Market Landscape, Company Competitiveness Analysis, Recent Expansions, Capacity Analysis, Demand Analysis, Total Cost of Ownership, Market Forecast and Opportunity Analysis

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of oral solid dosage contract manufacturing market and its likely evolution in the mid-long term.
  • A general overview of oral solid dosage contract manufacturing, highlighting details on the various types and components of oral solid dose forms. Additionally, it presents information on the oral solid dosage manufacturing process. Further, it highlights the emerging trends in oral solid dosage manufacturing market, featuring information on the commonly outsourced manufacturing operations. The chapter concludes with a discussion on key considerations while selecting a CDMO partner, the affiliated risks and future perspectives of growth in this industry. 
  • A detailed assessment of the overall market landscape of the companies offering contract services for oral solid dosage manufacturing, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, company ownership (privately held and publicly owned), type of service(s) offered (pre-formulation / formulation development, process development, analytical, scale-up, packaging, regulatory and others), type of finished dosage form(s) manufactured (tablets, capsules, granules, multi-particulates and others), type of packaging offered (bottles, blisters, sachets / pouches / bags, inhalers, and others), scale(s) of operation (preclinical, clinical, and commercial) and additional manufacturing capabilities (continuous oral solid dosage manufacturing and highly potent oral solid dosage manufacturing. 
  • A detailed competitiveness analysis of oral solid dosage contract manufacturing service providers based on supplier strength (in terms of years of experience) and service strength (considering type of service(s) offered, type of finished dosage form(s), type of packaging offered, scale(s) of operation, regulatory certification(s) and location of facilities). 
  • A detailed analysis of the capabilities of oral solid dosage contract manufacturers established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), based on several relevant parameters, including type of type of service(s) offered, type of finished dosage form(s) manufactured, type of packaging offered and scale(s) of operation. It also features information on the location of manufacturing facilities of the service providers.
  • Elaborate profiles of key players engaged in the contract manufacturing of oral solids (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, its financial information (if available), details on its oral solid dosage service portfolio, manufacturing capabilities and facilities, and recent developments and an informed future outlook. 
  • An insightful make versus buy framework, highlighting the various factors that need to be taken into consideration by oral solid dosage drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO or CDMO partner.
  • A detailed analysis of the recent expansions (since 2018) undertaken by various service providers in order to augment their respective oral solid dosage contract manufacturing portfolios, based on a several relevant parameters, including year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of An estimate of the global installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), type of finished dosage form (tablets, capsules, and others) and key geographical regions (North America, Europe, and Asia-Pacific and Rest of the World). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
  • An informed estimate of the annual clinical and commercial demand for oral solid doses (in terms of volume of API), across key geographical regions and therapeutic areas.
  • A detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years. 
  • A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 300 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • A case study on the current market landscape of taste masking service providers for oral solids, providing information on scale of operation (preclinical / clinical and commercial), manufacturing scalability, other service(s) offered along with information on type of formulation (tablets, granules, capsules, semi-solids and others), end users (pharmaceutical, nutraceutical and others), techniques used for taste masking (hot melt extrusion, microencapsulation, coating, ion exchange resin and others), branch of healthcare (pediatrics, geriatrics and others) and regional capability. Further, the chapter includes the current market landscape of taste masking technology providers, providing information on technology name, techniques used, type of finished dosage form (tablets, capsules, powder and others), end users (pharmaceutical, nutraceutical and others) along with information on patent, availability of technology for partnerships and licensing. In addition, the chapter provides details on the year of establishment, company size and location of headquarters of companies providing taste masking services and technologies for oral solids.
  • A case study on the overall market landscape of bioavailability enhancement service providers for oral solids, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / micronization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, fine particles and semi-solids).

One of the key objectives of the market report was to estimate the current opportunity and the future growth potential of the oral solid dosage contract manufacturing market in the forecast period. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, including type of finished dosage form (tablets, capsules, multi-particulates, powders and others), type of packaging (bottles, blisters, sachets,  inhalers, and others), scale of operation (pre-commercial and commercial), company size (small, mid-sized, large and very large), therapeutic areas (oncological disorder, neurological disorder, cardiovascular disorder, infectious disease, metabolic disorder, respiratory disorder, immunological disorder, genetic disorder, gastrointestinal disorder and others), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is oral solid dosage?

Answer: Oral solid dosage is the final drug product, commonly tablets and capsules, that can be administered through oral route (by mouth)

Question 2: What is the global market size of oral solid dosage contract manufacturing market?

Answer: The current oral solid contract manufacturing market size is anticipated to be over USD 21 billion

Question 3: What is the current market landscape of oral solid dosage contract manufacturing market?

Answer: Presently, close to 570 companies are engaged in offering oral solid dosage contract manufacturing services through more than 880 manufacturing facilities worldwide

Question 4: How many contract service providers possess capabilities to handle oral solid therapies based on highly potent APIs (HPAPIs)?

Answer: Over 40% of the contract service providers engaged in oral solid dosage manufacturing claim to have the requisite capabilities for the safe handling and containment of highly potent oral solids.

Question 5: What are the factors driving the oral solid dosage contract manufacturing market?

Answer: The factors driving the oral solid dosage contract manufacturing market include the emergence of virtual pharmaceutical companies, and the surge in demand for novel oral solid formulations, such as such as pediatric / geriatric, taste-masked, abuse-deterrent and control release products that improve patient compliance

Question 6: Which region has the highest market share in the oral solid dosage contract manufacturing market?

Answer: North America captures around 60% share in the current oral solid dosage contract manufacturing market, followed by Europe

Question 7: What are the leading market segments in the oral solid dosage contract manufacturing market?

Answer: Currently, the oral solid dosage contract manufacturing market is dominated by tablet manufacturing and capsule manufacturing. This can be attributed to several advantages offered by these dosage forms, including portability, ease in swallowing, excellent bioavailability and medical adherence. Further, in terms of company size, established players (with over 10,000 employees) are likely to capture over 50% of the current and future market, owing to their enhanced capabilities and huge production capacities

Question 8: What is the growth rate (CAGR) in the oral solid dosage contract manufacturing market?

Answer: The oral solid dosage contract manufacturing market size is projected to grow at a CAGR of ~5% during the forecast period

Question 9: What are the upcoming trends in the oral solid dosage contract manufacturing market?

Answer: The market is presently witnessing the adoption of Industry 4.0 concepts, such as QbD and PAT. Further, several service providers are establishing / expanding their continuous manufacturing lines for the production of oral solids, thereby reducing manufacturing cost (by 15-30%), manpower (by 50-70%) and power consumption (by 40%)

Question 10: What are the current initiatives undertaken by big pharma players engaged in the oral solid dosage contract manufacturing market?

Answer: In order to tap the lucrative opportunity in this rapidly growing market, big pharma players have undertaken several initiatives, including strengthening product portfolio, establishing agreements, acquisitions and making investments. For instance, in August 2022, Catalent acquired Metrics Contract Services for USD 475 million to expand its high-potent and oral solid dosage manufacturing capabilities

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Type of Dosage Forms
3.3. Overview of Oral Solid Dosage Forms
3.3.1. Components of Oral Solid Dosage Forms
3.3.2. Classification of Oral Solid Dosage Forms
3.3.3. Manufacturing of Oral Solid Dosage Forms
3.3.4. Emerging Trends in Oral Solid Dosage Manufacturing

3.4. Overview of Oral Solid Contract Manufacturing
3.4.1. Services Offered by CMOs and CDMOs for Oral Solid Manufacturing
3.4.2. Key Considerations While Selecting a CDMO or CMO Partner
3.4.3. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations

3.5. Future Perspectives

4. ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS (CMOs): MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Oral Solid Dosage CMOs: List of Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Ownership
4.2.5. Analysis by Type of Service(s) Offered
4.2.6. Analysis by Type of Finished Dosage Form
4.2.7. Analysis by Type of Tablet(S) Manufactured
4.2.8. Analysis by Type of Capsule(s) Manufactured
4.2.9. Analysis by Type of Multi-particulate(s) Manufactured
4.2.10. Analysis by Type of Primary Packaging Offered
4.2.11. Analysis by Scale of Operation
4.2.12. Analysis by High Potency Drug Manufacturing
4.2.13. Analysis by Availability of Continuous Manufacturing
4.2.14. Analysis by Regulatory Certifications / Accreditations

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in North America
5.4.1. Peer Group I: Companies in the US
5.4.2. Peer Group II: Companies in Canada

5.5. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Europe
5.5.1. Peer Group III: Companies in EU5
5.5.2. Peer Group IV: Other European Countries
5.6. Company Competitiveness Analysis: Oral Solid Contract Manufacturers based in Asia-Pacific and Rest of the World
5.6.1. Peer Group V: Companies in India
5.6.2. Peer Group VI: Companies in China
5.6.3. Peer Group VII: Companies in Japan
5.6.4. Peer Group VIII: Companies in Other Asia-Pacific and rest of the World

5.7. Company Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers

6. REGIONAL CAPABILITY ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Overall Landscape of Oral Solid Dosage Contract Manufacturing Facilities
6.4. Oral Solid Dosage Contract Manufacturers in North America
6.5. Oral Solid Dosage Contract Manufacturers in Europe
6.6. Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World

7. COMPANY PROFILES
7.1. Chapter Overview

7.2. Oral Solid Dosage Contract Manufacturing Service Providers: North America
7.2.1. Alcami
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.2.1. Manufacturing Capabilities and Facilities
7.2.1.3. Recent Developments and Future Outlook

7.2.2. Cambrex
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.2.1. Manufacturing Capabilities and Facilities
7.2.2.3. Recent Developments and Future Outlook

7.2.3. Catalent
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.3.1. Manufacturing Capabilities and Facilities
7.2.3.4. Recent Developments and Future Outlook

7.3. Oral Solid Dosage Contract Manufacturing Service Providers: Europe
7.3.1. Aenova
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Service Portfolio
7.3.1.3.1. Manufacturing Capabilities and Facilities
7.3.1.4. Recent Developments and Future Outlook

7.3.2. Almac
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Service Portfolio
7.3.2.3.1. Manufacturing Capabilities and Facilities
7.3.2.4. Recent Developments and Future Outlook

7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Information
7.3.3.3. Service Portfolio
7.3.3.3.1. Manufacturing Capabilities and Facilities
7.3.3.4. Recent Developments and Future Outlook

7.4. Oral Solid Dosage Contract Manufacturing Service Providers: Asia-Pacific and Rest of the World
7.4.1. Hetero Drugs
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.2.1. Manufacturing Capabilities and Facilities
7.4.1.3. Recent Developments and Future Outlook

7.4.2. Ind-Swift Laboratories
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Service Portfolio
7.4.2.3.1. Manufacturing Capabilities and Facilities
7.4.2.4. Recent Developments and Future Outlook

7.4.3. Rubicon Research
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.2.1. Manufacturing Capabilities and Facilities
7.4.3.3. Recent Developments and Future Outlook

8. MAKE VERSUS BUY DECISION FRAMEWORK
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Oral Solid Dosage Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario 1
8.3.2. Scenario 2
8.3.3. Scenario 3
8.3.4. Scenario 4
8.4. Concluding Remarks

9. RECENT EXPANSIONS
9.1. Chapter Overview
9.2. Oral Solid Dosage Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Year and Type of Expansion
9.2.4. Analysis by Type of Oral Solid Dosage Form(s) Involved
9.2.5. Analysis by Type of Expansion and Oral Solid Dosage Form(s) Involved
9.2.6. Analysis by Type of Service(s) Offered
9.2.7. Analysis by Scales of Operation
9.2.8. Analysis by Location of Facility
9.2.9. Expansions Focused on Highly Potent Compounds

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.2.1. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Number of Finished Dosages)
10.2.1.1. Analysis by Company Size
10.2.1.2. Analysis by Scale of Operation
10.2.1.3. Analysis by Type of Finished Dosage Form
10.2.1.4. Analysis by Location of Manufacturing Facility
10.2.1.5. Analysis by Company Size and Type of Finished Dosage Form
10.2.1.6. Analysis by Company Size and Location of Manufacturing Facility
10.2.1.7. Analysis by Scale of Operation and Location of Manufacturing Facility

10.2.2. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Amount of API)
10.2.2.1. Analysis by Company Size
10.2.2.2. Analysis by Scale of Operation
10.2.2.3. Analysis by Type of Finished Dosage Form
10.2.2.4. Analysis by Company Size and Type of Finished Dosage Form
10.2.2.5. Analysis by Company Size and Location of Manufacturing Facility
10.2.2.6. Analysis by Scale of Operation and Location of Manufacturing Facility

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Annual Demand for Oral Solid Doses, 2023-2035

11.4. Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035
11.4.1. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035
11.4.1.1. Annual Outsourced Commercial Demand for Oral Solid Doses in North America, 2023-2035
11.4.1.2. Annual Outsourced Commercial Demand for Oral Solid Doses in Europe, 2023-2035
11.4.1.3. Annual Outsourced Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035
11.4.2. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035
11.4.2.1. Annual Outsourced Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035
11.4.2.2. Annual Outsourced Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035
11.4.2.3. Annual Outsourced Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035
11.4.2.4. Annual Outsourced Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035
11.4.2.5. Annual Outsourced Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035
11.4.2.6. Annual Outsourced Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035
11.4.2.7. Annual Outsourced Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035
11.4.2.8. Annual Outsourced Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035
11.4.2.9. Annual Outsourced Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035
11.5. Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035
11.5.1. Annual Outsourced Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035
11.5.1.1. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035
11.5.1.2. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035
11.5.1.3. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035
11.6. Correlation between Annual Demand and Capacity

12. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS
12.1. Chapter Overview
12.2. Key Parameters
12.3. Assumptions and Methodology
12.4. Sample Dataset for the Estimation of Total Cost of Ownership
12.5. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20
12.6. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20
12.6.1. Total Cost of Ownership for Oral Solid Contract Manufacturing Organizations: Analysis by CapEx, Y0
12.6.2. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by OpEx, Y0-Y20
12.7. Concluding Remarks

13. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURERS
13.1. Chapter Overview
13.2. Regulatory Guidelines in North America
13.2.1. The US Scenario
13.2.1. Canadian Scenario
13.3. Regulatory Guidelines in Europe
13.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
13.4.1. Chinese Scenario
13.4.2. Indian Scenario
13.4.3. Japanese Scenario
13.4.4. South Korean Scenario
13.4.5. Australian Scenario
13.4.6. Brazilian Scenario
13.5. Oral Solid Dosage CMOs: Information on Approval From Various Regulatory Authorities
13.6. Bubble Analysis: Regional Regulatory Summary

14. CASE STUDY ON TASTE MASKING SERVICES AND TECHNOLOGIES: MARKET LANDSCAPE
14.1. Chapter Overview
14.2. Taste Masking and Taste Assessment Service Providers
14.2.1. Analysis by Year of Establishment
14.2.2. Analysis by Company Size
14.2.3. Analysis by Location of Headquarters
14.2.4. Analysis by Year of Establishment and Location of Headquarters

14.3. Taste Masking and Taste Assessment Services: Overall Market Landscape
14.3.1. Analysis by Service(s) Offered
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Other Service(s) Offered
14.3.4. Analysis by Type of Formulation(s)
14.3.5. Analysis by End Users
14.3.6. Analysis by Techniques Used for Taste Masking
14.3.7. Analysis by Branch of Healthcare
14.3.8. Analysis by Regional Capability

15. CASE STUDY ON BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES: MARKET LANDSCAPE
15.1. Chapter Overview
15.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
15.2.1. Analysis by Year of Establishment
15.2.2. Analysis by Company Size
15.2.3. Analysis by Location of Headquarters
15.2.4. Analysis by Bioavailability Enhancement Principle
15.2.5. Analysis by Bioavailability Enhancement Approach
15.2.5.1. Analysis by Solid Dispersion Approaches
15.2.5.2. Analysis by Size Reduction Approaches
15.2.5.3. Analysis by Lipid-Based Approaches
15.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
15.2.6. Analysis by Dosage Form
15.2.7. Analysis by Route of Administration

16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.2.1. Overall Oral Solid Dosage Contract Manufacturing Market, 2023-2035
16.2.2. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
16.2.2.1. Tablet Manufacturing Market, 2023-2035
16.2.2.2. Capsule Manufacturing Market, 2023-2035
16.2.2.3. Powder Manufacturing Market, 2023-2035
16.2.2.4. Multi-particulates Manufacturing Market, 2023-2035
16.2.2.5. Other Finished Dosage Forms Manufacturing Market, 2023-2035
16.2.3. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
16.2.3.1. Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
16.2.3.2. Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
16.2.3.3. Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
16.2.3.4. Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
16.2.3.5. Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035
16.2.3.6. Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035
16.2.4. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
16.2.4.1. Oral Solid Dosage Contract Manufacturing Market for Pre-Commercial Scale, 2023-2035
16.2.4.2. Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
16.2.5. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Company Size
16.2.5.1. Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035
16.2.5.2. Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035
16.2.5.3. Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035
16.2.5.4. Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035
16.2.6. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
16.2.6.1. Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035
16.2.6.2. Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035
16.2.6.3. Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035
16.2.6.4. Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035
16.2.6.5. Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035
16.2.6.6. Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035
16.2.6.7. Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035
16.2.6.8. Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035
16.2.6.9. Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035
16.2.7. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
16.2.7.1. Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
16.2.7.2. Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
16.2.7.3. Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
16.2.7.4. Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
16.2.7.5. Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035

17. EXECUTIVE INSIGHTS

18. CONCLUDING REMARKS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Service(s) Landscape
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Demand Analysis
Figure 2.6 Executive Summary: Total Cost of Ownership
Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 2.8 Executive Summary: Case Study on Taste Masking Service Providers
Figure 2.9 Executive Summary: Case Study on Bioavailability Enhancement Service Providers
Figure 3.1 Properties of Dosage Forms
Figure 3.2 Types of Dosage Forms
Figure 3.3 Advantages and Disadvantages of Oral Solid Dosage Forms
Figure 3.4 Properties of Pharmaceutical Excipient
Figure 3.5 Type of Oral Solid Dosage Forms
Figure 3.6 Classification of Orally Administered Tablets
Figure 3.7 Tablet Processing Methods
Figure 3.8 Oral Solid Dosage Manufacturing Process
Figure 3.9 Services Offered by CDMOs and CMOs for Oral Solid Dosage
Figure 3.10 Key Considerations While Selecting a CDMO or CMO Partner
Figure 4.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size
Figure 4.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.4 World Map Representation: Distribution by Geography
Figure 4.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership
Figure 4.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Service(s) Offered
Figure 4.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form
Figure 4.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured
Figure 4.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured
Figure 4.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s) Manufactured
Figure 4.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered
Figure 4.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation
Figure 4.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing
Figure 4.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing
Figure 4.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certification / Accreditation
Figure 5.1 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in the US
Figure 5.2 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Canada
Figure 5.3 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in the EU5
Figure 5.4 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Other European Countries
Figure 5.5 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in India
Figure 5.6 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in China
Figure 5.7 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Japan
Figure 5.8 Company Competitiveness Analysis: Oral Solid Contract Manufacturers Based in Other Asia-Pacific and Rest of the World
Figure 5.9 Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers
Figure 6.1 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 6.2 Oral Solid Dosage Contract Manufacturing: North America Scenario (I / II)
Figure 6.2 Oral Solid Dosage Contract Manufacturers: North America Scenario (II / II)
Figure 6.4 Oral Solid Dosage Contract Manufacturing: Europe Scenario (I / II)
Figure 6.5 Oral Solid Dosage Contract Manufacturers: Europe Scenario (II / II)
Figure 6.5 Oral Solid Dosage Contract Manufacturing: Asia-Pacific and Rest of the World Scenario (I / II)
Figure 6.6 Oral Solid Dosage Contract Manufacturers: Asia-Pacific and Rest of the World Scenario (II / II)
Figure 7.1 Catalent: Annual Revenues, FY 2017- FY 2022 (USD Billion)
Figure 7.2 Catalent: Distribution of FY 2022 Revenues by Business Segment
Figure 7.3 Aenova: Annual Revenues, FY 2017- FY 2021 (EUR Million)
Figure 7.4 Aenova: Distribution of FY 2021 Revenues by Type of Business Segment
Figure 7.5 Almac: Annual Revenues, FY 2017- FY 2021 (GBP Million)
Figure 7.6 Lonza: Annual Revenues, FY 2017- FY 2022 (CHF Billion)
Figure 7.7 Lonza: Distribution of FY 2022 Revenues by Type of Business Segment
Figure 7.8 Ind-Swift Laboratories: Annual Revenues, FY 2017- FY 2022 (INR Billion)
Figure 8.1 Make versus Buy Decision Making Framework
Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 9.4 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved
Figure 9.5 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved
Figure 9.6 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 9.7 Recent Expansion: Distribution by Scale of Operation
Figure 9.8 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 9.9 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 9.10 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion
Figure 10.1 Annual Minimum, Average and Maximum Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size: Sample Data Set
Figure 10.2 Distribution by Minimum, Average and Maximum Weight of Various Finished Dosage Forms: Sample Data Set
Figure 10.3 Distribution by Minimum, Average and Maximum Share of API in Various Finished Dosage Forms: Sample Data Set
Figure 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size
Figure 10.5 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Figure 10.6 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form
Figure 10.7 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility
Figure 10.8 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form
Figure 10.9 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility
Figure 10.10 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 10.11 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size
Figure 10.12 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Amount of API): Distribution by Scale of Operation
Figure 10.13 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form
Figure 10.14 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form
Figure 10.15 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility
Figure 10.16 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 11.1 Demand Analysis: Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.2 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)
Figure 11.3 Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.4 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)
Figure 11.5 Commercial Outsourced Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)
Figure 11.6 Commercial Outsourced Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)
Figure 11.7 Commercial Outsourced Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
Figure 11.8 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
Figure 11.9 Commercial Outsourced Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)
Figure 11.10 Commercial Outsourced Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)
Figure 11.11 Commercial Outsourced Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)
Figure 11.12 Commercial Outsourced Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)
Figure 11.13 Commercial Outsourced Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)
Figure 11.14 Commercial Outsourced Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)
Figure 11.15 Commercial Outsourced Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)
Figure 11.16 Commercial Outsourced Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)
Figure 11.17 Commercial Outsourced Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)
Figure 11.18 Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Figure 11.19 Clinical Outsourced Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)
Figure 11.20 Clinical Outsourced Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)
Figure 11.21 Clinical Outsourced Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)
Figure 11.22 Clinical Outsourced Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)
Figure 11.23 Annual Outsourced Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)
Figure 11.24 Oral Solid Dosage Contract Manufacturing: Correlation between Demand and Capacity, 2023-2035
Figure 12.1 Total Cost of Ownership: Types of Capital Expenditures (CapEx)
Figure 12.2 Total Cost of Ownership: Types of Operational Expenditures (OpEx)
Figure 12.3 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 12.4 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
Figure 12.5 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
Figure 12.6 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
Figure 12.7 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
Figure 13.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 13.2 Regulatory Landscape for Oral Solid Dosage CMOs: Distribution by Certifications / Accreditations Received
Figure 13.3 Bubble Analysis: Regional Regulatory Summary
Figure 14.1 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment
Figure 14.2 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size
Figure 14.3 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters
Figure 14.4 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 14.5 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered
Figure 14.6 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation
Figure 14.7 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered
Figure 14.8 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)
Figure 14.9 Taste Masking and Taste Assessment Services: Distribution by End Users
Figure 14.10 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking
Figure 14.11 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare
Figure 14.12 Taste Masking and Taste Assessment Services: Distribution by Regional Capability
Figure 15.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 15.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 15.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 15.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 15.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 15.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches
Figure 15.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 15.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 15.10 Bioavailability Enhancement Service Providers: Distribution by Other Approaches
Figure 15.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 15.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 16.1 Oral Solid Dosage Contract Manufacturing: Market Forecast Approach
Figure 16.2 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.3 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form
Figure 16.4 Tablet Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.5 Capsule Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.6 Powder Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.7 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.8 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)
Figure 16.9 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging (USD Billion)
Figure 16.10 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)
Figure 16.11 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)
Figure 16.12 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)
Figure 16.13 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)
Figure 16.14 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)
Figure 16.15 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)
Figure 16.16 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation (USD Billion)
Figure 16.17 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)
Figure 16.18 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)
Figure 16.19 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion)
Figure 16.20 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)
Figure 16.21 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)
Figure 16.22 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)
Figure 16.23 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)
Figure 16.24 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area (USD Billion)
Figure 16.25 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)
Figure 16.26 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)
Figure 16.27 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)
Figure 16.28 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)
Figure 16.29 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)
Figure 16.30 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)
Figure 16.31 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)
Figure 16.32 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)
Figure 16.33 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)
Figure 16.34 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion)
Figure 16.35 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)
Figure 16.36 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)
Figure 16.37 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 16.38 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)
Figure 16.39 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

List Of Tables

Table 3.1 Commonly Used Excipients in Tablet Formulation
Table 3.2 Contrasting Characteristics: Film-coated and Sugar-coated Tablets
Table 3.3 Contrasting Characteristics: Hard Gelatin and Soft Gelatin Capsules
Table 4.1 Oral Solid Dosage Contract Manufacturing: List of Companies
Table 4.2 Oral Solid Dosage Contract Manufacturers: Information on Service(s) Offered
Table 4.3 Oral Solid Dosage Contract Manufacturers: Information on Type of Finished Dosage Form Manufactured
Table 4.4 Oral Solid Dosage Contract Manufacturers: Information on Type of Tablets and Capsules Manufactured
Table 4.5 Oral Solid Dosage Contract Manufacturers: Information on Type of Multi-particulate(s) Manufactured
Table 4.6 Oral Solid Dosage Contract Manufacturers: Information on Type of Primary Packaging Offered
Table 4.7 Oral Solid Dosage Contract Manufacturers: Information on Scale of Operation and Additional Manufacturing Capabilities
Table 4.8 Oral Solid Dosage Contract Manufacturers: Information on Regulatory Certifications and Accreditations
Table 6.1 Oral Solid Dosage Contract Manufacturers based in North America: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.2 Oral Solid Dosage Contract Manufacturers based in North America: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 6.3 Oral Solid Dosage Contract Manufacturers based in Europe: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.4 Oral Solid Dosage Contract Manufacturers based in Europe: Information Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 6.5 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities
Table 6.6 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities
Table 7.1 Oral Solid Dosage Contract Manufacturing Service Providers: List of Profiled Companies
Table 7.2 Alcami: Company Snapshot
Table 7.3 Alcami: Service Portfolio
Table 7.4 Alcami: Recent Developments and Future Outlook
Table 7.5 Cambrex: Company Snapshot
Table 7.6 Cambrex: Service Portfolio
Table 7.7 Cambrex: Oral Solid Manufacturing Facilities,
Table 7.8 Cambrex: Recent Developments and Future Outlook
Table 7.9 Catalent: Company Snapshot
Table 7.10 Catalent: Service Portfolio
Table 7.11 Catalent: Oral Solid Manufacturing Facilities
Table 7.12 Catalent: Recent Developments and Future Outlook
Table 7.13 Aenova: Company Snapshot
Table 7.14 Aenova: Service Portfolio
Table 7.15 Aenova: Oral Solid Manufacturing Facilities
Table 7.16 Aenova: Recent Developments and Future Outlook
Table 7.17 Almac: Company Snapshot
Table 7.18 Almac: Service Portfolio
Table 7.19 Almac: Oral Solid Manufacturing Facilities,
Table 7.20 Almac: Recent Developments and Future Outlook
Table 7.21 Lonza: Company Snapshot
Table 7.22 Lonza: Service Portfolio
Table 7.23 Lonza: Oral Solid Manufacturing Facilities
Table 7.24 Lonza: Recent Developments and Future Outlook
Table 7.25 Hetero Drugs: Company Snapshot
Table 7.26 Hetero Drugs: Service Portfolio
Table 7.27 Hetero Drugs: Recent Developments and Future Outlook
Table 7.28 Ind-Swift Laboratories: Company Snapshot
Table 7.29 Ind-Swift Laboratories: Service Portfolio
Table 7.30 Ind-Swift Laboratories: Oral Solid Manufacturing Facilities
Table 7.31 Rubicon Research: Company Snapshot
Table 7.32 Rubicon Research: Service Portfolio
Table 7.33 Rubicon Research: Oral Solid Manufacturing Facilities
Table 9.1 Oral Solid Dosage Contract Manufacturers: List of Recent Expansions, 2018-2022
Table 9.2 Recent Expansions: Information on Type of Oral Solid Dosage Form(s) Involved, Type of Service(s) Offered and Scale(s) of Operation, 2018-2022
Table 10.1 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Type of Finished Dosage Form): Sample Data Set
Table 10.2 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size): Sample Data Set
Table 10.3 Distribution by Amount of API in Various Types of Oral Solid Dosage Forms: Sample Data Set
Table 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size
Table 11.1 Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 11.2 Demand and Supply Analysis: Information on Annual Capacity Utilization Rates
Table 11.3 Annual Outsourced Demand (Base and Optimistic Scenarios): 2023-2035 (Metric Tons)
Table 12.1 Total Cost of Ownership: Sample Dataset for CapEx
Table 12.2 Total Cost of Ownership: Sample Dataset for OpEx
Table 13.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 13.2 Health Canada’s Good Manufacturing Practices Guidelines for Tablets and Capsules
Table 13.3 Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities
Table 13.4 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 14.1 List of Taste Masking and Taste Assessment Service Providers
Table 14.2 Taste Masking and Taste Assessment Services: Information on Service(s) Offered, Scale of Operation and Other Service(s) Offered
Table 14.3 Taste Masking and Taste Assessment Services: Information on Type of Formulation
Table 14.4 Taste Masking and Taste Assessment Services: Information on End Users, Techniques Used for Taste Masking, Branch of Healthcare and Regional Capability
Table 15.1 List of Bioavailability Enhancement Service Providers
Table 15.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle
Table 15.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach
Table 15.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches
Table 15.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 15.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches
Table 15.7 Bioavailability Enhancement Service Providers: Information on Other Approaches
Table 15.8 Bioavailability Enhancement Service Providers: Information on Dosage Form, ,
Table 15.9 Bioavailability Enhancement Service Providers: Information on Route of Administration
Table 17.1 Bushu Pharmaceuticals: Key Highlights
Table 19.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment
Table 19.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size
Table 19.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters
Table 19.4 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 19.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership
Table 19.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Services Offered
Table 19.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form
Table 19.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured
Table 19.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured
Table 19.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s)
Table 19.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered
Table 19.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation
Table 19.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing
Table 19.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing
Table 19.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 19.16 Catalent: Annual Revenues, FY 2017 – FY 2022 (USD Billion)
Table 19.17 Aenova: Annual Revenues, FY 2017 – FY 2021 (EUR Million)
Table 19.18 Almac: Annual Revenues, FY 2017 – FY 2021 (GBP Million)
Table 19.19 Lonza: Annual Revenues, FY 2017 – FY 2022 (CHF Billion)
Table 19.20 Ind-Swift Laboratories: Annual Revenues, FY 2017 – FY 2022 (INR Billion)
Table 19.21 Recent Expansions: Cumulative Year-wise Trend, 2018-2022
Table 19.22 Recent Expansions: Distribution by Type of Expansion
Table 19.23 Recent Expansions: Distribution by Year and Type of Expansion
Table 19.24 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved
Table 19.25 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved
Table 19.26 Recent Expansions: Distribution by Type of Service(s) Offered
Table 19.27 Recent Expansion: Distribution by Scale of Operation
Table 19.28 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 19.29 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 19.30 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion
Table 19.31 Annual Global Capacity for Oral Solid Contract Manufacturing (Number of FDF Units): Distribution by Company Size and Range of Installed Capacity
Table 19.32 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Average Weight of Various Finished Dosage Forms): Sample Data Set
Table 19.33 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Share of API in Various Finished Dosage Forms): Sample Data Set
Table 19.34 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size
Table 19.35 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Table 19.36 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form
Table 19.37 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility
Table 19.38 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form
Table 19.39 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility
Table 19.40 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 19.41 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API Processed): Distribution by Company Size
Table 19.42 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation
Table 19.43 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form
Table 19.44 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form
Table 19.45 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility
Table 19.46 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 19.47 Annual Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)
Table 19.48 Demand Analysis: Annual Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.49 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)
Table 19.50 Annual Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.51 Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)
Table 19.52 Commercial Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)
Table 19.53 Commercial Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)
Table 19.54 Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
Table 19.55 Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
Table 19.56 Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)
Table 19.57 Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)
Table 19.58 Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)
Table 19.59 Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)
Table 19.60 Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)
Table 19.61 Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)
Table 19.62 Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)
Table 19.63 Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)
Table 19.64 Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)
Table 19.65 Annual Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)
Table 19.66 Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)
Table 19.67 Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)
Table 19.68 Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)
Table 19.69 Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)
Table 19.70 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 19.71 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
Table 19.72 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
Table 19.73 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
Table 19.74 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
Table 19.75 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment
Table 19.76 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size
Table 19.77 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters
Table 19.78 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters
Table 19.79 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered
Table 19.80 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation
Table 19.81 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered
Table 19.82 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)
Table 19.83 Taste Masking and Taste Assessment Services: Distribution by End Users
Table 19.84 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking
Table 19.85 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare
Table 19.86 Taste Masking and Taste Assessment Services: Distribution by Regional Capability
Table 19.87 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 19.88 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 19.89 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 19.90 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 19.91 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 19.92 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 19.93 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches
Table 19.94 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 19.95 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 19.96 Bioavailability Enhancement Service Providers: Distribution by Other Approaches
Table 19.97 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 19.98 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 19.99 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
Table 19.100 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form
Table 19.101 Tablet Manufacturing Market, 2023-2035 (USD Billion)
Table 19.102 Capsule Manufacturing Market, 2023-2035 (USD Billion)
Table 19.103 Powder Manufacturing Market, 2023-2035 (USD Billion)
Table 19.104 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)
Table 19.105 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)
Table 19.106 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging
Table 19.107 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)
Table 19.108 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)
Table 19.109 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)
Table 19.110 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)
Table 19.111 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)
Table 19.112 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)
Table 19.113 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation
Table 19.114 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)
Table 19.115 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)
Table 19.116 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size
Table 19.117 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)
Table 19.118 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)
Table 19.119 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)
Table 19.120 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)
Table 19.121 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area
Table 19.122 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)
Table 19.123 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)
Table 19.124 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)
Table 19.125 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)
Table 19.126 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)
Table 19.127 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)
Table 19.128 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)
Table 19.129 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)
Table 19.130 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)
Table 19.131 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Geographical Regions (USD Billion)
Table 19.132 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)
Table 19.133 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)
Table 19.134 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 19.135 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)
Table 19.136 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Aar Biosys
  2. Aaschem Life Care
  3. Aavis Pharmaceuticals
  4. AbbVie
  5. AbbVie Contract Manufacturing
  6. Abiogen Pharma
  7. ABITEC
  8. Accu-Break Pharmaceuticals
  9. Acenzia
  10. ACIC Pharmaceuticals
  11. Acino
  12. Acme Group
  13. ACS Dobfar
  14. Actiza Pharmaceutical 
  15. Adare Pharma Solutions
  16. Adept Pharma
  17. Adipharm
  18. Aenova 
  19. Afriplex
  20. Aiomedic Pharmaceuticals 
  21. AiPing Pharmaceutical
  22. Aizant Drug Research Solutions
  23. Ajinomoto Bio-Pharma Services
  24. Akrikhin
  25. AKRIKHIN (subsidiary of Polpharma)
  26. Akums Drugs & Pharmaceuticals
  27. Alaron Products
  28. Alban Pharma
  29. Albia Biocare
  30. AlbyPharma
  31. Alcami
  32. Alencure Biotech
  33. Alfa Pharma
  34. Algen Healthcare
  35. Alkermes
  36. Alkermes Contract Pharma Services (acquired by Alkermes)
  37. Allay Pharmaceuticals
  38. Allegiant Health
  39. Allianz Biosciences
  40. Almac
  41. Alpen Pharma
  42. Altasciences
  43. Altus Drug Development
  44. Alvogen
  45. Ambi Pack
  46. Amerilab Technologies
  47. Amneal Pharmaceuticals
  48. AMP (Acquired by Pact)
  49. Amster Labs
  50. Angelini Pharma
  51. ANI Pharmaceuticals
  52. Ankur Drugs and Pharma
  53. Anqiu Lu'an Pharmaceutical
  54. Aphena Pharma Solutions
  55. API Pharma Tech
  56. Apicore
  57. APL Pharma Specials
  58. Apotex
  59. Appco Pharma
  60. Aptuit (acquired by Evotec)
  61. Arafarma
  62. Arbro Pharmaceuticals
  63. Arcadia Biotechnology
  64. Archimedis Healthcare
  65. Ardena
  66. Aristo Pharma
  67. Arizona Custom Blends
  68. Arkle Healthcare
  69. Arvincare
  70. Ascendia Pharmaceuticals 
  71. Ashish Life Science
  72. Asiltus Bio Pharma 
  73. Aspen Pharmacare
  74. Astam Healthcare
  75. Asterisk Healthcare
  76. Asymchem Laboratories
  77. Athena Pharmaceutiques
  78. Aurex Laboratories
  79. Aurigene
  80. Aurigene Pharmaceutical Services
  81. Aurisco Pharmaceutical
  82. Aurobindo Pharma
  83. AustarPharma
  84. AustinPx
  85. Australian Pharmaceutical Manufacturers (subsidiary of Pact Group)
  86. Avara Pharmaceutical Services
  87. Avema Pharma Solutions
  88. AVVA Pharmaceuticals
  89. Axone Pharma
  90. Axxelent Pharma Science
  91. BAHRAIN PHARMA
  92. Bal Pharma
  93. Batterjee Pharma
  94. Bausch Health
  95. BDR Pharmaceuticals
  96. Belco Pharma
  97. bene-Arzneimittel
  98. Bennet Pharmaceuticals
  99. BePharBel
  100. Beximco Pharmaceuticals
  101. Bharat Biologics
  102. BHI Biohealth International
  103. Bidu Biotech
  104. Binnopharm Group
  105. BioBrick Pharma
  106. BioDuro-Sundia (subsidiary of Advent International)
  107. Biofabri
  108. BIOLAB
  109. Bion Healthcare
  110. Biostem Pharma
  111. Biotropics Malaysia Berhad
  112. Biozoc
  113. Biropharma
  114. BJ LifeSciences
  115. BJP Laboratories
  116. Bluegum Pharmaceuticals
  117. Bluepharma
  118. Bora Pharmaceuticals 
  119. Bristol Laboratories
  120. BSP Pharmaceuticals
  121. Bushu Pharmaceuticals
  122. Cadila Pharmaceuticals
  123. Cambrex
  124. CanCap Pharmaceutical
  125. Canonpharma Production
  126. Capcium
  127. Caplin Point Laboratories
  128. Caprichem
  129. Capsule Filling
  130. Carlsbad Technology 
  131. Casca Remedies
  132. Catalent
  133. Cenexi
  134. Centaur Pharmaceuticals
  135. Chanelle Pharma
  136. Chartwell Pharmaceuticals
  137. China Chemical & Pharmaceutical
  138. Chongqing Huapont Pharmaceutical
  139. Cian Healthcare 
  140. Ciron Drugs
  141. Clinpak Technologies
  142. Cloverty
  143. CMIC Group
  144. CMPS
  145. Coating Place
  146. Concord Drugs
  147. Confab Laboratories
  148. Contract Pharmacal
  149. Cooper Pharma
  150. CordenPharma
  151. COREALIS Pharma
  152. CoreRx
  153. Coripharma
  154. Cosmas Research Labs
  155. CPC Scientific
  156. Cris Pharma
  157. Curtis Health Caps
  158. Custom Pharma Services
  159. Daito Pharmaceutical
  160. Dalong biotechnology
  161. Dalton Pharma Services
  162. DBK Pharma
  163. DBK Pharmaceutical
  164. Delorbis Pharmaceuticals
  165. Delpharm
  166. Dexa Group
  167. DM Pharma 
  168. Don Valley Pharma
  169. Doppel Farmaceutici
  170. Douglas Pharmaceuticals
  171. DR. D PHARMA
  172. Dr. Pfleger
  173. Dwarkesh Pharmaceuticals
  174. Edge Pharmaceuticals
  175. EirGen Pharma
  176. Eisai
  177. EL Laboratories
  178. Elfin
  179. Elikem pharmaceuticals
  180. Elite Pharmaceuticals
  181. EmergoPharm
  182. Enomark Pharma
  183. E-Pharma Trento
  184. Epic Pharma
  185. Eskayef Pharmaceuticals (subsidiary of Transcom Group)
  186. eubioco
  187. Eurofins Scientific
  188. Europharma Alliance
  189. EVALAR
  190. Exeltis
  191. Experic
  192. Fareva
  193. Farmacápsulas
  194. Farmak
  195. Farmasierra
  196. Fealth Life Care
  197. Fermion
  198. Fermion (subsidiary of Orion)
  199. Ferron Par Pharmaceuticals (subsidiary of DEKA)
  200. Flamingo Pharmaceuticals
  201. Formurex
  202. Friulchem
  203. FTF Pharma
  204. Fuji Capsule
  205. Fuji Chemical
  206. Fuji Pharma
  207. FULTON MEDICINALI
  208. Future Pak
  209. Galena Pharma
  210. Galenicum
  211. Gebro Pharma
  212. Gemini Pharmaceuticals
  213. Genesis Biotech
  214. Genuone Sciences
  215. Genvion
  216. GFR Pharma
  217. Glatt
  218. Globela Pharma
  219. Gracure Pharmaceuticals
  220. Granules India
  221. Grindeks
  222. Grunenthal
  223. Grupo Azevedos
  224. Gruppo Farmaimpresa
  225. Guardian Drug Company
  226. H.L. Healthcare
  227. Handok 
  228. Hänseler
  229. Hanuchem Laboratories
  230. HBM Pharma
  231. Health Biotech
  232. Healthy Life Pharma
  233. Helios Pharmaceuticals
  234. Help Pharmaceuticals
  235. HENNIG
  236. HERMES PHARMA
  237. Hetero Drugs
  238. HillBliz Pharmaceuticals
  239. Hi-Tech Pharma
  240. Hi-Tech Pharmaceuticals
  241. HKS Health Solutions
  242. HOF Pharmaceuticals
  243. Hovione 
  244. Huayi Pharmaceuticals
  245. Hudi Pharma
  246. HWI Group
  247. IBERFAR
  248. ICE Pharma
  249. IDT Australia
  250. Ikop Pharma (formerly known as lIUM Pharmacy)
  251. Indoco Remedies
  252. Ind-Swift Laboratories
  253. Inducare Pharma
  254. Ingenus Pharmaceuticals
  255. InLabs
  256. InnoGenerics
  257. Innopharmax
  258. Innova Captab
  259. Inpac Pharma
  260. Intas Pharmaceuticals
  261. i-Pharmaceuticals
  262. Iwaki Seiyaku Sakura Factory 
  263. iX Syrinx
  264. JB Chemicals & Pharmaceuticals (JBCPL)
  265. Jemopharm
  266. JIPS Pharmaceuticals
  267. JoinHub Pharma
  268. JW Nutritional
  269. Kavya Pharma
  270. Kiara Health
  271. Kinegic Pharmaceuticals
  272. KLOCKE GRUPPE
  273. Kokando
  274. Kolmar Korea (acquired by IMM Private Equity)
  275. KP Pharmaceutical Technology
  276. Krishlar Pharmaceuticals
  277. Kryptochem Medicament
  278. Kyoto Pharmaceutical
  279. KYZEL REMEDIES
  280. Labatec Pharma
  281. Labo Phytophar
  282. Laboratoria Wolfs
  283. Laboratórios Atral
  284. Laboratorios Farmacéuticos ROVI
  285. Laboratorios Lesvi (subsidiary of Neuraxpharm)
  286. Laboratorios Nova Argentia
  287. LAGAP
  288. Lannett
  289. Laurus Labs
  290. Laurus Synthesis
  291. Lezaa Biotech 
  292. LGM Pharma
  293. Lifekyor Pharmaceuticals
  294. Lifevision Healthcare 
  295. Limhealth
  296. LIPOSOMA
  297. LIQUIDCAPSULE Manufacturing
  298. Logos Pharma
  299. Lomapharm
  300. Lonza
  301. Losan Pharma
  302. Lotus
  303. Lubrizol Life Science Health
  304. Lustrel Laboratoires
  305. Macter
  306. Madras Pharmaceuticals
  307. Makers Nutrition
  308. Mapaex
  309. Martin Dow Pharmaceuticals
  310. Mascot Health Series
  311. Max Life Sciences
  312. MAXIPLUS
  313. Maxtar Bio-Genics
  314. Mayne Pharma 
  315. McGuff Pharmaceuticals
  316. McW Healthcare
  317. Mecosan Labs
  318. Mediboon Pharma
  319. Medical Product Laboratories
  320. Medical Products Laboratories (MPL)
  321. medicef pharma
  322. Medichem
  323. Medicofarma 
  324. Medinomics Health Care
  325. Mediterranean Pharmaceutical Company
  326. Mediva Lifecare
  327. Mediwin Pharmaceuticals
  328. Medizia Biotech
  329. Medlab Pharmaceuticals
  330. Meridian Enterprises
  331. Metamorf Lifesciences
  332. Metlar Formulations
  333. Metrics Contract Services (a subsidiary of Catalent)
  334. Micro Labs
  335. Micro-Sphere
  336. Mikart
  337. MinskInterCaps
  338. Mipharm
  339. Mirpharm
  340. Mission Pharmacal
  341. Montavit
  342. MSN Laboratories
  343. Murty Pharmaceuticals
  344. Mythus Pharmaceuticals
  345. Nanz Pharma
  346. Natco Pharma
  347. Natural Farm
  348. Navone Specialities
  349. Nectar Lifesciences
  350. NerPharMa
  351. Neuraxpharm
  352. NextPharma
  353. NHP Land
  354. Ningbo Menovo Pharmaceutical 
  355. Nipro Patch
  356. Noble Pharma
  357. Noreva Biotech
  358. Norit
  359. Norwich Pharma Services
  360. Noucor
  361. Novalab Healthcare
  362. Nutragen Pharma
  363. Nutricorp
  364. NUVISAN
  365. Nvron Life Science
  366. Oasis Laboratories
  367. Olainfarm
  368. OLIC Thailand (subsidiary of Fuji Pharma)
  369. Olimp Laboratories
  370. Olive Healthcare
  371. Oman Pharmaceutical Products
  372. Omicron Pharma
  373. Orchard Vale Naturals (division of EastWest BioScience)
  374. Orchid Pharma
  375. Orlife Healthcare
  376. Orofino Pharmaceuticals
  377. Pace Life Sciences Laboratory
  378. Pacific India
  379. PanTheryx
  380. Paragon Laboratories
  381. Park Pharmaceuticals
  382. Parsolex
  383. Pax Healthcare 
  384. PCI Pharma Services
  385. Penmix
  386. Pfizer CentreOne
  387. Pharma Synth Formulations
  388. Pharma Tech Industries
  389. PHARMACARE PREMIUM 
  390. Pharmaceutics International (Pii)
  391. Pharmactive
  392. PharmaHopers
  393. Pharmaline
  394. Pharmaniaga Berhad
  395. PharmaPath
  396. Pharma-Q
  397. Pharmascience
  398. PharmaSynth
  399. Pharmatec
  400. Pharmathen
  401. Pharmed Healthcare
  402. Pharmer
  403. Pharmia
  404. Pidolma Healthcare
  405. Pii
  406. Pillar5 Pharma
  407. PIQ-PHARMA
  408. Piramal Pharma Solutions
  409. PiSA Farmaceutica
  410. PMRS
  411. Polaris
  412. Polfa Tarchomin
  413. Polpharma
  414. Porton Pharma Solutions
  415. PPF Hasco-Lek
  416. Principle Healthcare
  417. Priyans Drugs
  418. Probiotec
  419. Procaps
  420. Progressive Laboratories
  421. PT Eisai Indonesia (subsidiary of Eisai)
  422. PuraCap Pharmaceutical
  423. Qingdao BNP BioScience
  424. Qingdao Haosail Science
  425. QLife Pharma
  426. Qualiphar
  427. Quality Chemical Laboratories
  428. Quay Pharmaceuticals
  429. Quotient Sciences
  430. Radiant Pharmaceuticals
  431. Radico Remedies
  432. Rafarm
  433. Recipharm
  434. Redwing Pharma
  435. Remington Pharmaceuticals
  436. Ripcord Pharmaceuticals
  437. Rivopharm
  438. Robinson Pharma
  439. Romapharm
  440. Rontis
  441. Ropack
  442. Rottendorf Pharma
  443. Rovi
  444. Royce Pharma Manufacturing
  445. Rubicon Research
  446. RV Lifesciences (formerly known as Atra Pharmaceutical)
  447. S M Pharmaceuticals
  448. S.Zhaveri Pharmakem
  449. Sabinsa
  450. Safe u Pharmaceuticals
  451. Sai Life Sciences
  452. Salvat
  453. Salvus Pharma
  454. Sancilio & Company
  455. Sanctus Global Formulations (formerly known as Crescent Therapeutics)
  456. Sandoz
  457. Sanico
  458. Sannova
  459. SANTA Pharm
  460. Sanwa Kagaku Kenkyusho (subsidiary of Suzuken)
  461. Saphnix Lifesciences 
  462. Sarvodaya Drugs and Pharmaceuticals 
  463. Sarvotham Care
  464. Sava Healthcare
  465. SB LifeSciences
  466. Scanpharm
  467. SCHWITZ BIOTECH 
  468. SEID Lab
  469. Selvok Pharmaceutical 
  470. Senate Laboratories
  471. Serán BioScience
  472. Servier 
  473. SFI Health
  474. SGS Pharmaceuticals
  475. Sharon Bio-Medicine 
  476. Shaurya Drugs
  477. Shilpa Medicare
  478. Shionogi
  479. Siegfried
  480. SigmaPharm Laboratories
  481. Siit
  482. Silvanols
  483. Sino Therapeutics
  484. SirioPharm
  485. Skyepharma
  486. SNU Biocare
  487. Societal CDMO
  488. Softcaps
  489. Softgel Healthcare (associate of Madras Pharmaceuticals)
  490. Sonamed Pharma
  491. Sopharma
  492. Sovereign Pharmaceuticals
  493. Sreshtha Life Sciences
  494. Stason Pharmaceuticals
  495. Stellar Manufacturing
  496. Steril-Gene
  497. Sterling Pharmaceutical Services
  498. SUBSTIPHARM
  499. Suheung Capsule
  500. Sunrise Pharmaceutical
  501. Surepharm Services
  502. Surewin Healthcare
  503. Swiss Parenterals
  504. Swiss Pharma
  505. Synergy United Pharmachem
  506. Synerlab Group
  507. Syngen Biotech
  508. Syngene
  509. Synokem Pharmaceuticals
  510. Synovia Pharma (formerly known as Sanofi Bangladesh and subsidiary of Beximco Pharmaceuticals)
  511. Sypharma
  512. Tablets (India)
  513. Tai Heng Industry
  514. TAIYO Pharma Tech 
  515. Taj Pharmaceuticals
  516. Tapemark
  517. Tasnim Pharmaceutical
  518. Tatchempharmpreparaty
  519. TECNALIA (member of the Basque Research and Technology Alliance)
  520. Tedor Pharma
  521. Teika Pharmaceutical
  522. Theon Pharmaceuticals
  523. Thompson & Capper
  524. Tismor Health & Wellness
  525. TOA Pharmaceutical
  526. TriRx
  527. TRITON Pharmaceuticals
  528. Trividia Manufacturing Solutions (formerly known as formerly P.J. Noyes Company)
  529. Trugen Pharmaceuticals
  530. TRUMAC HEALTHCARE
  531. TSI Group
  532. TTY Biopharm Company
  533. Tulex Pharmaceuticals
  534. Ultratech India
  535. Umalaxmi Organics
  536. Unichem Laboratories
  537. Unimarck Pharma
  538. Unimark Remedies
  539. Unison Chemical Works
  540. Unither Pharmaceuticals
  541. Uniza
  542. UPM Pharmaceuticals
  543. Upperton Pharma Solutions
  544. Uriach
  545. URSAPHARM Arzneimittel
  546. US Pharma Lab
  547. ValueMED Pharma
  548. Vee Excel Drugs & Pharmaceuticals
  549. VENIPHARM
  550. Vici Health Sciences
  551. Vieco Pharmaceuticals
  552. Vital Products
  553. Vitex Pharmaceuticals
  554. Vivimed Labs
  555. Viwit Pharmaceuticals
  556. VTF Pharmaceutical
  557. VWR INTERNATIONAL
  558. VxP Pharma
  559. Walter Healthcare
  560. WAMIN
  561. Weefsel Pharma
  562. Wejust (Beijing) International Trading
  563. Wellona Pharma
  564. Wellspring Pharma Services
  565. Wen Ken Drug Company 
  566. White Heron Pharmaceutical
  567. Wiewelhove
  568. Windlas Healthcare
  569. Wockhardt
  570. WuXi AppTec
  571. Xenosys Biotech
  572. XL Laboratories
  573. Yao Pharma (subsidiary of Fosun Pharma)
  574. Zenith Healthcare
  575. Zenlabs
  576. Zeon Biotech
  577. Zhejiang Hisun Pharmaceutical
  578. Zubrix Healthcare
  579. Zumax Biocare

Source 1: https://www.formulationbio.com/tablets.html
Source 2: https://www.contractpharma.com/issues/2019-03-01/view_features/oral-solids-endure-evolve/

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.